In a randomized phase-II trial for metastatic colorectal cancer patients who were refractory or intolerant to standard chemotherapies, TAS-102 also improved overall survival regardless of the KRAS tumor status (16). This evidence concerns the gene KRAS and metastatic colorectal cancer.